Table 3.
Most commonly reported grade 3/4 adverse events for safety populations and patients treated with pomalidomide (POM) + LoDEX for 1 year or more.
Most commonly reported grade 3/4 adverse events for safety populations and patients treated with pomalidomide (POM) + LoDEX for 1 year or more.